$HALO

AI 分析

生成於 May 11, 2026

AI Score
72/ 100
Hold$HALO

Halozyme Therapeutics

$HALONASDAQHealthcareMid-Cap

Halozyme develops drug-delivery technologies including ENHANZE for subcutaneous delivery of biologics.

Market Cap
$12.0B
Revenue (TTM)
$0.9B
+15.0%
Net Income (TTM)
$0.35B
+20.0%
EPS (TTM)
$2.50
P/E Ratio
28.0
Dividend Yield
0.0%
52-Week Range
$38-$62
Beta
0.72
Dimension Scores
Fundamental
70
Technical
68
Sentiment
72
Risk / Reward
70
Momentum
74
FundTechSentRiskMome
Financial Health
Profitability
75moderate
Growth
77strong
Liquidity
78strong
Solvency
72strong
Efficiency
68strong

Valuation, technical analysis, investment thesis, risk assessment and more for $HALO

Free · No credit card required

免責聲明: AI 生成的分析僅供教育參考,不構成投資建議。請始終諮詢合格的理財顧問。

探索更多

用 AI 分析任意股票

獲取涵蓋基本面、技術面、情緒面、風險評估和投資論點的結構化研究報告——約 60 秒完成。